Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) insider Timothy Rolph sold 6,250 shares of the company's stock in a transaction on Monday, April 7th. The shares were sold at an average price of $35.88, for a total transaction of $224,250.00. Following the completion of the sale, the insider now owns 169,721 shares of the company's stock, valued at approximately $6,089,589.48. This trade represents a 3.55 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Timothy Rolph also recently made the following trade(s):
- On Wednesday, March 5th, Timothy Rolph sold 12,500 shares of Akero Therapeutics stock. The shares were sold at an average price of $44.53, for a total transaction of $556,625.00.
- On Wednesday, February 5th, Timothy Rolph sold 18,750 shares of Akero Therapeutics stock. The stock was sold at an average price of $56.51, for a total transaction of $1,059,562.50.
- On Monday, January 27th, Timothy Rolph sold 31,250 shares of Akero Therapeutics stock. The shares were sold at an average price of $55.77, for a total value of $1,742,812.50.
Akero Therapeutics Stock Down 6.8 %
Shares of NASDAQ AKRO opened at $34.82 on Friday. The stock has a market capitalization of $2.77 billion, a price-to-earnings ratio of -9.29 and a beta of -0.18. Akero Therapeutics, Inc. has a 52 week low of $17.86 and a 52 week high of $58.40. The firm has a 50-day moving average price of $45.27 and a 200 day moving average price of $35.81. The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.05.
Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last posted its quarterly earnings results on Friday, February 28th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.98) by ($0.01). Equities research analysts anticipate that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.
Institutional Trading of Akero Therapeutics
Several large investors have recently bought and sold shares of AKRO. GF Fund Management CO. LTD. acquired a new position in shares of Akero Therapeutics during the 4th quarter worth $41,000. Sterling Capital Management LLC raised its position in Akero Therapeutics by 764.3% during the fourth quarter. Sterling Capital Management LLC now owns 1,789 shares of the company's stock worth $50,000 after acquiring an additional 1,582 shares during the last quarter. Quarry LP purchased a new stake in shares of Akero Therapeutics in the fourth quarter valued at about $83,000. Summit Investment Advisors Inc. grew its position in shares of Akero Therapeutics by 6.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,092 shares of the company's stock valued at $197,000 after purchasing an additional 450 shares during the last quarter. Finally, Hsbc Holdings PLC grew its position in shares of Akero Therapeutics by 8.5% in the fourth quarter. Hsbc Holdings PLC now owns 7,886 shares of the company's stock valued at $220,000 after purchasing an additional 621 shares during the last quarter.
Analyst Upgrades and Downgrades
AKRO has been the topic of a number of recent research reports. Citigroup boosted their target price on Akero Therapeutics from $65.00 to $80.00 and gave the company a "buy" rating in a report on Tuesday, January 28th. HC Wainwright boosted their price objective on shares of Akero Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a research note on Monday, March 3rd. Bank of America upgraded shares of Akero Therapeutics from a "neutral" rating to a "buy" rating and raised their target price for the stock from $35.00 to $63.00 in a research note on Thursday, January 30th. UBS Group boosted their price target on shares of Akero Therapeutics from $42.00 to $109.00 and gave the stock a "buy" rating in a research note on Friday, January 31st. Finally, Canaccord Genuity Group raised their price objective on shares of Akero Therapeutics from $56.00 to $73.00 and gave the company a "buy" rating in a research report on Tuesday, January 28th. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $76.29.
Read Our Latest Research Report on AKRO
Akero Therapeutics Company Profile
(
Get Free Report)
Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
